SOLVENTUM CORPORATION (SOLV) Free cash flow
- Free cash flow · 12 months (USD): Value $-118.00M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -1.42%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-118.00M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $209.00M − $327.00M ≈ $-118.00M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -1.42% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-118.00M ÷ $8.31B × 100 ≈ -1.42% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $209.00M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.15× | Operating cash flow / net income. Period ending 2026-06-30. $209.00M ÷ $1.43B ≈ 0.15× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 209.00M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 327.00M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -118.00M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 8.31B USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 1.43B USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-118.00M | (m) | $209.00M | $327.00M | (m) | $8.31B | (m) | $1.43B | (m) | (m) | -1.42% | 0.15× |
| 2026-03-31 | $-203.00M | (m) | $151.00M | $354.00M | (m) | $8.26B | (m) | $1.43B | (m) | (m) | -2.46% | 0.11× |
| 2025-12-31 | $-10.00M | (m) | $369.00M | $379.00M | (m) | $8.32B | (m) | $1.56B | (m) | (m) | -0.12% | 0.24× |
| 2025-09-30 | $50.00M | (m) | $493.00M | $443.00M | (m) | $8.40B | (m) | $1.52B | (m) | (m) | 0.60% | 0.32× |
| 2025-06-30 | $147.00M | (m) | $586.00M | $439.00M | (m) | $8.39B | (m) | $380.00M | (m) | (m) | 1.75% | 1.54× |
| 2025-03-31 | $385.00M | (m) | $772.00M | $387.00M | (m) | $8.31B | (m) | $379.00M | (m) | (m) | 4.63% | 2.04× |
| 2024-12-31 | $805.00M | (m) | $1.19B | $380.00M | (m) | $8.25B | (m) | $479.00M | (m) | (m) | 9.75% | 2.47× |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $1.63B | (m) | $1.92B | $290.00M | (m) | $8.20B | (m) | $1.35B | (m) | (m) | 19.82% | 1.42× |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $1.43B | (m) | $1.68B | $251.00M | (m) | $8.13B | (m) | $1.34B | (m) | (m) | 17.56% | 1.25× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B |